Regulus slashes IPO price; Durata Therapeutics to move R&D to Connecticut; Black mamba venom contains powerful pain reliever;

Conversations on Twitter :

 @FierceBiotech: Merger deal gives generic drugmaker control of troubled BioSante. More | Follow @FierceBiotech

 @JohnCFierce: 2012 Fierce 15 winner Aragon raises $50M for 509 program. That's $88M this year. More | Follow @JohnCFierce

 @RyanMFierce: BioSante goes the way of the M&A. More | Follow @RyanMFierce

> Regulus has slashed its IPO price from a range of $10 to $12 a share down to only $4. Story

> Durata Therapeutics has gained some incentives from Connecticut as it preps a move to the state. Durata will move R&D and other operations from New Jersey to Connecticut, with promises to eventually create 80 new jobs. Release

> Antaras Pharma plans to raise $47 million through the sale of shares. The company is developing new delivery systems for therapies. Report

> Ember Therapeutics, a 2012 Fierce 15 company, says it has gained the exclusive option rights to intellectual property for three key small molecule targets: retinaldehyde dehydrogenase 1 (Aldh1a1), thioesterase superfamily member 1 (Them1), and TRPV4. Release

> Reuters has profiled Belgium's growing biotech industry. Story

Pharma News

@FiercePharma: J&J's trying to block testimony from ex-FDA chief David Kessler, who calls its Risperdal marketing "deeply troubling." More | Follow @FiercePharma

> Teva yanks Wellbutrin copy after FDA says it's not equivalent to brand. News

> India nixes Pfizer's patent on cancer-fighter Sutent. Story

> Mylan sues FDA to revoke Ranbaxy's Diovan exclusivity. Report

Medical Device News

 @FierceMedDev: Alere has reached a deal with the FDA on Dx production, looking to move past May's recall of 800K test kits. More | Follow @FierceMedDev

 @MarkHFierce: Sony may be boosting its involvement in med tech, but investors are worried the company is going down a sinkhole. More | Follow @MarkHFierce

 @DamianFierce: Medtronic's next-gen renal denervation device takes a page from the St. Jude tech Medtronic earlier dismissed. More | Follow @DamianFierce

> Life Technologies, CollabRx, forge molecular Dx data deal. Article

> Judge: BD violated Hologic's patents. News

> Tyrx gains Canadian regualtory nod for antibacterial envelope. Story

Pharma Manufacturing News

> Square Pharmaceuticals opening 2 plants in Bangladesh. News

> Merck whacking 20% of jobs at Ireland API plant. Story

> New Janssen distribution hub consolidates European supply chain. Article

Vaccines News

> Novartis vaccines unit's future hangs on Bexsero approval. Article

> NIH awards $1.38M to professor for HIV vaccine research. Item

> Merck's Gardasil earns high safety marks. Story

> Flu vaccine manufacturers face steep odds. News

And Finally… French scientists say they have discovered that the venom from the lethal black mamba snake contains a pain reliever that is as strong as morphine with none of the side effects. Story

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.